Ticker brief
SVRA
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
12
authors 14d
6
crowd 14d
-0.1σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-03 → 2026-10-16 · now +0.00 (−1 bearish … +1 bullish)
Who spoke6
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @BiopharmIQ | B | · | 3 | +0.37 |
| @BPharmCatalyst | C | · | 3 | +0.00 |
| @OzmosiHealth | C | · | 3 | +0.10 |
| @Quantumup1 | C | +0.10 | 1 | +0.40 |
| @Tickeron | C | +1.53 | 1 | +0.15 |
| @PolycarpFX | B | +0.16 | 1 | +0.12 |
Recent signals12of 12 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-16 | @BPharmCatalyst | +0.00 | Publishes a biotech watchlist for catalysts expected in mid-winter 2026. | · | tweet ↗ |
| 2026-10-14 | @BPharmCatalyst | +0.00 | Flags three biotech companies with potentially market-moving FDA decisions due in November. | · | tweet ↗ |
| 2026-10-13 | @OzmosiHealth | +0.10 | Savara scheduled Phase 3 molgramostim results for October 20. | · | tweet ↗ |
| 2026-10-13 | @OzmosiHealth | +0.10 | Savara scheduled Phase 2 molgramostim results for October 21. | · | tweet ↗ |
| 2026-10-13 | @PolycarpFX | +0.12 | Dice emoji implies a speculative positive lean toward Savara. | · | tweet ↗ |
| 2026-10-13 | @BiopharmIQ | +0.00 | Biotech opening-news board pairs catalysts with contemporaneous price moves. | · | tweet ↗ |
| 2026-10-12 | @OzmosiHealth | +0.10 | Savara will present a new trial analysis and long-term data at CHEST 2026. | · | tweet ↗ |
| 2026-10-11 | @Tickeron | +0.15 | Summarizes SVRA's pullback, FDA decision date, trial data, consensus target, and cash position | · | tweet ↗ |
| 2026-10-09 | @BPharmCatalyst | +0.00 | Six-month watchlist of upcoming PDUFA catalyst decisions; ticker list capped at six. | · | tweet ↗ |
| 2026-10-07 | @Quantumup1 | +0.40 | Citizens reiterates Market Outperform and a $10 target, citing high approval odds and undervaluation. | · | tweet ↗ |
| 2026-10-03 | @BiopharmIQ | +0.55 | Provides modeled FDA outcome probabilities and stock-move ranges supporting a positive SVRA setup. | · | tweet ↗ |
| 2026-10-03 | @BiopharmIQ | +0.55 | Summarizes modeled November FDA odds and move profiles for three biotech catalysts. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.